Pfizer reported a Q3 revenue of $16.65B, down 5.9% due to declining COVID product sales. Teva delivered an 11th consecutive quarter of growth, with revenue up 3.4% to $4.48B driven by AUSTEDO. Pfizer beat EPS estimates by 36% while Teva exceeded estimates by 16%. Pfizer operates at a 35.3% operating margin, generating $4.60B in quarterly operating cash flow and paying a 6.6% dividend yield. Teva targets a 30% non-GAAP operating margin by 2027 and just launched a generic liraglutide injection. Pfizer reaffirmed full-year revenue guidance of $61.0 to $64.0B and raised adjusted EPS guidance to $3.00-$3.15. Teva raised full-year EPS guidance to $2.55-$2.65 non-GAAP and reaffirmed revenue of $16.8-$17.0B. Pfizer offers a 6.6% dividend yield and faces the challenge of replacing declining COVID revenue with organic growth. Teva focuses on growth and trades at 10x forward earnings, showing 40% earnings growth last quarter. Many Americans are realizing they can retire earlier than expected by reworking their portfolios.

Read more at Yahoo Finance: Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue